Sanofi, GSK start phase II COVID-19 vaccine study

By The Science Advisory Board staff writers

February 22, 2021 -- Sanofi and GlaxoSmithKline (GSK) are starting a large phase II study of their COVID-19 vaccine.

The two pharmas are developing an adjuvanted recombinant protein vaccine. Their phase II study, which will enroll 720 adult volunteers, will evaluate three different antigen doses to determine the best strategy for phase III development. If successful, the partners plan to move the candidate into phase III in the second quarter.


Copyright © 2021 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?